Scholarlink

Background <p>Breast cancer remains the most common malignancy among women worldwide. While traditional computed tomography (CT) scans and image-guided radiotherapy are widely used for breast cancer diagnosis and treatment, their efficacy is often limited.</p> Methods and results <p>In this study, we successfully synthesized human serum albumin (HSA)-based KBiF<sub>4</sub> nanoclusters through a simple one-pot biomimetic mineralization strategy. Compared to the clinical contrast agent iohexol, KBiF<sub>4</sub>@HSA significantly enhances dual-energy CT (DECT) imaging contrast at high keV levels, offering improved diagnostic accuracy for breast cancer. Furthermore, KBiF<sub>4</sub>@HSA exhibits a remarkable ability to scavenge elevated glutathione (GSH) levels and promote reactive oxygen species (ROS) generation. When combined with radiotherapy, KBiF<sub>4</sub>@HSA substantially increases X-ray dose deposition at tumor sites, leading to enhanced DNA damage and suppression of breast cancer progression. Importantly, KBiF<sub>4</sub>@HSA demonstrates excellent biocompatibility in vivo, with no significant tissue damage or inflammation observed.</p> Conclusions <p>This study presents a novel approach for the development of biocompatible DECT contrast agents and radiosensitizers, offering a promising strategy to enhance breast cancer diagnosis and treatment. However, the efficacy of this approach needs to be further validated across diverse breast cancer subtypes to ensure its broad applicability, which emphasizes the necessity for continued research to fully translate this innovative technology into clinical practice.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Human serum albumin-based KBiF4@HSA nanoclusters for dual-energy computed tomography and glutathione-scavenging radiotherapy of breast cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月18日

查看全文
  • Yuelin Huang,
  • Zhenghai Lu,
  • Huanhuan Liu,
  • Ningxin Yang,
  • Yanhong Chen,
  • Chunting Wang,
  • Weixi Huang,
  • Jingjing Hu,
  • Dengbin Wang,
  • Defan Yao

摘要

Background

Breast cancer remains the most common malignancy among women worldwide. While traditional computed tomography (CT) scans and image-guided radiotherapy are widely used for breast cancer diagnosis and treatment, their efficacy is often limited.

Methods and results

In this study, we successfully synthesized human serum albumin (HSA)-based KBiF4 nanoclusters through a simple one-pot biomimetic mineralization strategy. Compared to the clinical contrast agent iohexol, KBiF4@HSA significantly enhances dual-energy CT (DECT) imaging contrast at high keV levels, offering improved diagnostic accuracy for breast cancer. Furthermore, KBiF4@HSA exhibits a remarkable ability to scavenge elevated glutathione (GSH) levels and promote reactive oxygen species (ROS) generation. When combined with radiotherapy, KBiF4@HSA substantially increases X-ray dose deposition at tumor sites, leading to enhanced DNA damage and suppression of breast cancer progression. Importantly, KBiF4@HSA demonstrates excellent biocompatibility in vivo, with no significant tissue damage or inflammation observed.

Conclusions

This study presents a novel approach for the development of biocompatible DECT contrast agents and radiosensitizers, offering a promising strategy to enhance breast cancer diagnosis and treatment. However, the efficacy of this approach needs to be further validated across diverse breast cancer subtypes to ensure its broad applicability, which emphasizes the necessity for continued research to fully translate this innovative technology into clinical practice.